Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Free Cash Flow (2016 - 2025)

Cardiff Oncology's Free Cash Flow history spans 15 years, with the latest figure at -$6.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 34.55% year-over-year to -$6.7 million; the TTM value through Dec 2025 reached -$38.7 million, down 2.58%, while the annual FY2025 figure was -$38.7 million, 2.58% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$6.7 million at Cardiff Oncology, up from -$10.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$4.3 million in Q2 2021 and bottomed at -$13.7 million in Q1 2025.
  • The 5-year median for Free Cash Flow is -$7.7 million (2021), against an average of -$8.3 million.
  • The largest YoY upside for Free Cash Flow was 34.55% in 2025 against a maximum downside of 75.14% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$7.6 million in 2021, then fell by 23.33% to -$9.4 million in 2022, then grew by 23.7% to -$7.1 million in 2023, then tumbled by 42.54% to -$10.2 million in 2024, then skyrocketed by 34.55% to -$6.7 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Free Cash Flow are -$6.7 million (Q4 2025), -$10.9 million (Q3 2025), and -$7.4 million (Q2 2025).